Phase 1 Relapsed or Refractory Clinical Trials
41 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 41 trials
Recruiting
Phase 1
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Advanced Relapsed or Refractory Germ Cell TumoursAdvanced Relapsed or Refractory Endometrial CancerAdvanced Relapsed or Refractory Ovarian Cancer
Boehringer Ingelheim187 enrolled13 locationsNCT07306559
Recruiting
Phase 1
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC180 enrolled29 locationsNCT05652335
Recruiting
Phase 1
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC80 enrolled15 locationsNCT06604715
Recruiting
Phase 1Phase 2
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.166 enrolled10 locationsNCT07116616
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Relapsed or Refractory Multiple Myeloma
Genentech, Inc.120 enrolled14 locationsNCT05927571
Recruiting
Phase 1
U96-CAR-T-Cells For R/R B-ALL
Relapsed or Refractory B Cell Leukemia and Lymphoma
The First Affiliated Hospital of Soochow University30 enrolled1 locationNCT07511426
Recruiting
Phase 1
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Relapsed or Refractory Hematologic Malignancies
Vanda Pharmaceuticals42 enrolled11 locationsNCT03838926
Recruiting
Phase 1
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.130 enrolled11 locationsNCT06375044
Recruiting
Phase 1
Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma
Relapsed or Refractory Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd18 enrolled1 locationNCT07453446
Recruiting
Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Relapsed or Refractory T Cell Lymphoma
Ono Pharmaceutical Co., Ltd.217 enrolled20 locationsNCT05079282
Recruiting
Phase 1
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Excyte Biopharma Ltd70 enrolled12 locationsNCT06574568
Recruiting
Phase 1Phase 2
Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients
Relapsed or Refractory Hodgkin's Lymphoma
Fondazione Italiana Linfomi - ETS122 enrolled32 locationsNCT05300282
Recruiting
Phase 1
Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
O&D BioTech Group CO., Limited18 enrolled1 locationNCT07369895
Recruiting
Phase 1
A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies
Relapsed or Refractory Lymphoid Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.22 enrolled1 locationNCT06718634
Recruiting
Phase 1
A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
Relapsed or Refractory Hematologic Malignancies
Qilu Pharmaceutical Co., Ltd.186 enrolled1 locationNCT07173595
Recruiting
Phase 1
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Relapsed or Refractory B-cell Malignancies
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.50 enrolled4 locationsNCT06980116
Recruiting
Phase 1
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Utah24 enrolled1 locationNCT06824701
Recruiting
Phase 1
Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital18 enrolled1 locationNCT07003555
Recruiting
Phase 1
Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital18 enrolled1 locationNCT07003568
Recruiting
Phase 1
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
PeproMene Bio, Inc.36 enrolled6 locationsNCT05370430